(preprint 1/27) (Peer Reviewed)
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682
Tardif et al., 1/27/2021, Double Blind Randomized Controlled Trial, Canada, North America, peer-reviewed, 44 authors.
risk of death, 43.9% lower, RR 0.56, p = 0.30, treatment 5 of 2235 (0.2%), control 9 of 2253 (0.4%), odds ratio converted to relative risk.
risk of mechanical ventilation, 46.8% lower, RR 0.53, p = 0.09, treatment 11 of 2235 (0.5%), control 21 of 2253 (0.9%), odds ratio converted to relative risk.
risk of hospitalization, 20.0% lower, RR 0.80, p = 0.07, treatment 101 of 2235 (4.5%), control 128 of 2253 (5.7%), odds ratio converted to relative risk.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.